Apixaban Tablets 2.5mg (14tabs/blister, 4blisters/box)

• Dossier: Ctd
• Transport Package: Free
• Specification: 2.5mg
• Trademark: Sinolead
• Origin: China
• Model NO.: tablets

Product Description

 

Basic Info.

 

Generic Name	Apixaban Tablets
Strength	2.5mg
Packing	14x4/box
Origin	China

Component:
Apixaban .

Character:

This product is a yellow film coating, after removing the coating, white to almost white

Indications:

For adult patients undergoing elective hip or knee replacement to prevent venous thromboembolic events (VTE)
 

Usage and dosage:

The recommended dose of this product is 2.5mg each time, taken orally twice a day with water, which is not affected by meals. The first dose should be taken between 12 and 24 hours after surgery. When deciding when to take medication in this window, doctors should consider both the potential benefits of early anticoagulation to prevent VTE and the risk of bleeding after surgery.
For patients undergoing hip replacement surgery: The recommended course of treatment is 32 to 38 days
For patients undergoing knee replacement: The recommended course of treatment is 10 to 14 days
In the event of a single missed dose, the patient should take this product immediately and then continue to take it twice daily. When switching from an injectable anticoagulant to this treatment, it can be started at the next dosing time point (and vice versa).

Matters needing attention:

Bleeding risk

As with other anticoagulants, patients taking Apixaban should be closely monitored for signs of bleeding. Apixaban should be used with caution in patients at risk for: congenital or acquired bleeding disorders; Active gastrointestinal ulcer disease; Bacterial endocarditis; Thrombocytopenia; Abnormal platelet function; History of hemorrhagic stroke; Uncontrolled severe hypertension; Recently had brain, spine, or eye surgery. Apixaban should be discontinued if severe bleeding occurs

Renal damage

Patients with mild or moderate kidney damage do not need to adjust the dose

Limited clinical data in patients with severe renal impairment (creatinine clearance of 15-29 mL /min) suggest elevated plasma concentrations of apixaban in this patient population and caution should be exercised when using apixaban alone or in combination with acetylsalicylic acid in these patients due to a possible increased risk of bleeding

Since there is no creatinine clearance. Clinical data of patients with 15ml/min or dialysis patients, and therefore Apixaban is not recommended for these patients

Elderly patients

There is limited clinical experience in the use of apixaban in combination with acetylsalicylic acid in elderly patients. Elderly patients should be cautious when taking these two drugs in combination because of a possible increased risk of bleeding.